Literature DB >> 22066711

Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis.

Esther Blanco1, Joseph Beyene, Anne Marie Maloney, Rowena Almeida, Marie-Chantal Ethier, Naomi Winick, Sarah Alexander, Lillian Sung.   

Abstract

The primary objective of the study was to describe non-relapse mortality (NRM) and the proportion of first events that are deaths in children with acute lymphoblastic leukemia (ALL). Secondary objectives were to identify groups at higher risk and to determine whether proportions have changed over time. We performed a systematic review of randomized pediatric ALL studies. From 1337 articles, 59 were included, comprising a total of 49 071 patients. The induction death rate was 1.38%, remission death rate was 1.94% and total NRM was 3.60%. Deaths were responsible for 53.84% of first events during induction and 13.03% in total. Standard risk patients had significantly lower NRM during remission. The year of study was not associated with NRM. The results of the study show that the rate of NRM in children with ALL is 3.60% and those with high risk ALL have significantly higher NRM during remission, but NRM has not changed over time. Future research should focus on the exploration of patient-related risk factors for NRM.

Entities:  

Mesh:

Year:  2012        PMID: 22066711     DOI: 10.3109/10428194.2011.639018

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Authors:  F Lennie Wong; Smita Bhatia; Wendy Landier; Liton Francisco; Wendy Leisenring; Melissa M Hudson; Gregory T Armstrong; Ann Mertens; Marilyn Stovall; Leslie L Robison; Gary H Lyman; Steven E Lipshultz; Saro H Armenian
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

Review 2.  Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-03-08

3.  Differences in Adverse Drug Events Among Pediatric Patients With and Without Cancer: Sub-Analysis of a Retrospective Cohort Study.

Authors:  Akira Koizumi; Yoshinori Ohta; Mio Sakuma; Rika Okamoto; Chisa Matsumoto; David W Bates; Takeshi Morimoto
Journal:  Drugs Real World Outcomes       Date:  2017-09

4.  Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis.

Authors:  Jason D Pole; Paul Gibson; Marie-Chantal Ethier; Tanya Lazor; Donna L Johnston; Carol Portwine; Mariana Silva; Sarah Alexander; Lillian Sung
Journal:  Br J Cancer       Date:  2017-01-17       Impact factor: 7.640

5.  JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.

Authors:  Kimberly Bodaar; Natsuko Yamagata; Anais Barthe; Jack Landrigan; Triona Ni Chonghaile; Melissa Burns; Kristen E Stevenson; Meenakshi Devidas; Mignon L Loh; Stephen P Hunger; Brent Wood; Lewis B Silverman; David T Teachey; Jules P Meijerink; Anthony Letai; Alejandro Gutierrez
Journal:  Leukemia       Date:  2022-04-11       Impact factor: 12.883

6.  Validation of a classification system for treatment-related mortality in children with cancer.

Authors:  Hadeel Hassan; Menie Rompola; Adam Woolf Glaser; Sally Elizabeth Kinsey; Robert Stephen Phillips
Journal:  BMJ Paediatr Open       Date:  2017-10-30

7.  Treatment-related mortality in newly diagnosed pediatric cancer: a population-based analysis.

Authors:  Paul Gibson; Jason D Pole; Tanya Lazor; Donna Johnston; Carol Portwine; Mariana Silva; Sarah Alexander; Lillian Sung
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.